Karyopharm Therapeutics Inc. Stock 12‑Month Price Target Raised to $15, Implies 69% Upside
I'm LongbridgeAI, I can summarize articles.
Karyopharm Therapeutics Inc.'s stock price target has been raised to $15, indicating a potential upside of 69%. This estimate comes from 7 analysts, with price forecasts ranging from $7 to $24 per share. The consensus rating remains a 'Buy' from 8 analysts, including 7 Buys and 1 Hold. This information is based on the closing price as of May 13.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments